anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Research using magnetic resonance imaging (MRI) suggests regional cerebral atrophy measures (e.g., frontal lobe, temporal lobe) may predict post-stroke outcomes. Clinical CT scans have excellent potential for use in research but it is unclear whether regional atrophy measures from CT are reliable compared to MRI reference standards.
METHODS: We used the Global Cortical Atrophy (GCA) scale to investigate reliability of atrophy measures on CT versus MRI scans from stroke patients originally recruited to the Oxford Cognitive Screening programme. Two raters provided standardised visual ratings at two timepoints. Weighted Kappa statistics assessed the reliability of regional atrophy scores. Spearman's correlation and a two-way repeated measures ANOVA assessed the reliability of the total score.
RESULTS: On clinically acquired neuroimaging from 98 stroke patients (mean/SD age = 70.97/11.99, 42 female, 84 ischaemic stroke), regional GCA scores on CT versus MRI showed fair to almost perfect intra-rater agreement (κ = .50-.87), substantial to almost perfect intra-rater agreement on CT (κ = .67-.88), and moderate to almost perfect intra-rater reliability on MRI (κ = .50-.89). Regional GCA scores showed mostly moderate to substantial inter-rater reliability on both CT and MRI (κ = .43-.69), except the temporal horns and parieto-occipital region. There was a strong correlation between total GCA scores on CT and MRI (r (96) = .87-.88, p < .001).
CONCLUSIONS: These results support the use of cerebral atrophy measures from CT in clinical research, as visual ratings showed generally good agreement between CT and MRI, between raters, and between timepoints.
This project seeks to create a paradigm shift in how the public views and utilizes vaccination services. Currently, community health centers remain the default setting for vaccination, and clinicians the default administrators. However, the general population may have difficulty accessing these clinics or trusting traditional vaccination providers, particularly if they are members of marginalized communities that have experienced medical discrimination. This project applies a two-pronged approach by addressing issues of trust and ease of access among the general population. This project is innovative by: a) mobilizing religious communities to discuss vaccines (to counter reported lack of information about vaccines among unvaccinated families) and b) training more community health workers in vaccination and in physically delivering vaccines through a "Vaccine-in-a-van" concept to facilitate ease in accessing vaccines. By mobilizing these individuals in the community settings where people live, work, worship, and learn, this project will expand vaccine information and services.

More specifically, this project plans to work with local health leaders in a low vaccination community in Aceh, Indonesia to identify social institutions that are part of children and families' daily lives; these could include houses of worship, schools, or community centers. This project will fund a mobile vaccine delivery unit to go to these locations to physically bring vaccines to the people and to link them with existing immunization clinic infrastructure. This project will also work towards changing the culture of child health and vaccination through substantial discussions and conversations with multiple levels of religious leaders at conferences.
The development of mRNA vaccines represented a significant achievement in response to the global health crisis during the SARS-CoV-2 pandemic. Evaluating vaccine efficacy entails identifying different anti-SARS-CoV-2 antibodies, such as total antibodies against the Receptor Binding Domain (RBD) of the S-protein, or neutralizing antibodies (NAbs). This study utilized an innovative PETIA-based kit to measure NAb, and the investigation aimed to assess whether levels of anti-RBD IgG and NAb uniformly measured 30 days after vaccination could predict individuals at a higher risk of subsequent infection in the months following vaccination. Among a cohort of healthy vaccinated healthcare workers larger than 6,000, 12 mRNA-1273- and 115 BNT162b2-vaccinated individuals contracted infections after the first two doses. The main finding is that neither anti-RBD IgG nor NAb levels measured at day 30 post-vaccination can be used as predictors of breakthrough infections (BI). Therefore, the levels of anti-SARS-CoV-2 antibodies detected shortly after vaccination are not the pivotal factors involved in antiviral protection, and other characteristics must be considered in understanding protection against infection. Furthermore, the levels of anti-RBD and NAbs followed a very similar pattern, with a correlation coefficient of r = 0.96. This robust correlation would justify ceasing the quantification of NAbs, as the information provided by both determinations is highly similar. This optimization would help allocate resources more efficiently and speed up the determination of individuals' humoral immunity status.
Disclosed are compositions comprising GML (Glycerol monolaurate), as active ingredient for killing Gram negative bacteria of the genus Helicobacter. For eradiction of H. pylori colonization or treatment of infections or other disease states resulting from H. pylori colonization, the GML composition may be administered in connection with another pharmaceutically active substance useful for treating gastrointestinal disorders such as a bismuth salt, e.g., bismuth subcitrate or bismuth subsalicylate, cimetidine, ranitidine, omeprazole, lansoprazole, antacids, urease inhibitors or combinations thereof. The invention also concerns methods of treatment comprising the administration of mucolytic agents and compositions of GML. Mucolytic agents reduce or eliminate the negative effects of mucus on the action of the GML antibacterial agent and allow the GML to act locally at the sites of infection present in the mucosal epithelia. Mucolytic agents decrease the viscosity and disrupt the integrity of the mucus by various mechanisms. Mucolytic sulfhydryl compounds such as N-alkyl-cysteines, Penicillamine, N-(2-mercaptopropionyl)- glycine and WR2721 (the thiophosphate derivative of mercaptoethyl-1,3-diaminopropane) reduce disulfide bridges of the mucin matrix. The mucus may also be disrupted by exposure to hydrolytic enzymes such as glycohydrolases and proteinases, which digest the mucin, and nucleases. In particular, the proteinase, pronase, is useful for disrupting the mucin matrix.
PURPOSE:To provide the titled hair-nourishing and hair-growing agent effective to facilitate the circulation of blood, keep the normal state of circulation, suppress the falling-off of the hair, and promote the growth of the hair, by adding carbon dioxide gas to a blood circulation promoting agent, and sealing the mixture of acidic nature in a pressure vessel. CONSTITUTION:The objective agent contains (A) 0.001-5wt% of a blood circulation promoting agent (e.g. dl-alpha-tocopherol acetate, extract of Swertia japonica, etc.) and (B) >=60ppm of carbon dioxide gas, and has a pH adjusted to <=7 (preferably 4.5-6.5). The agent facilitates the circulation of blood and keeps the normal circulation state by the vasodilating activity of carbon dioxide gas. A propellant gas is sealed together with the agent in the pressure vessel to attain a pressure of preferably 1.2-8kg/cm<2>G at 35 deg.C. The diameter and length of the ejection nozzle are preferably selected to 0.3-1.5mm. and 1-15cm, respectively to enable the application of the agent directly to the scalp in the form of foam or liquid without staining the hair.
The father's phone will be stolen and the father will record the researcher's phone number. After this stage, the researcher will perform a pre-test before the mother is discharged and will not have her perform any newborn care procedures. Fathers in the control group will continue to receive routine care. In Turkey, information about the basic care of the newborn is given only verbally by neonatal midwives and nurses before discharge. After these procedures, a final test will be applied to this group at the end of the 1st month and at the end of the 4th month.
The invention belongs to the technical field of microorganisms, and particularly relates to a bacteriocin Mycocin with antibacterial activity on various pathogenic bacteria and application thereof. The amino acid sequence of the bacteriocin Mycocin is shown as SEQ ID NO. 1; the nucleotide for synthesizing the bacteriocin Mycocin is shown as a sequence SEQ ID NO. 2. The bacteriocin Mycocin is produced from bacillus mycoides XIN-LX30, has high-efficiency antibacterial activity on various pathogenic bacteria such as listeria monocytogenes, bacillus cereus, streptococcus pyogenes, streptococcus suis, staphylococcus aureus, staphylococcus epidermidis and enterococcus faecalis, and is safe and low in toxicity. In addition Mycocin has better heat and alkali resistance than nisin. In conclusion, the bacteriocin Mycocin can be used for preparing food preservatives, feed additives, antibacterial drugs and the like, and has wide application prospect.
Genomic mechanisms enhancing risk in males may contribute to sex bias in autism. The ubiquitin protein ligase E3A gene (Ube3a) affects cellular homeostasis via control of protein turnover and by acting as transcriptional coactivator with steroid hormone receptors. Overdosage of Ube3a via duplication or triplication of chromosomal region 15q11-13 causes 1 to 2% of autistic cases. Here, we test the hypothesis that increased dosage of Ube3a may influence autism-relevant phenotypes in a sex-biased manner. We show that mice with extra copies of Ube3a exhibit sex-biasing effects on brain connectomics and autism-relevant behaviors. These effects are associated with transcriptional dysregulation of autism-associated genes, as well as genes differentially expressed in 15q duplication and in autistic people. Increased Ube3a dosage also affects expression of genes on the X chromosome, genes influenced by sex steroid hormone, and genes sex-differentially regulated by transcription factors. These results suggest that Ube3a overdosage can contribute to sex bias in neurodevelopmental conditions via influence on sex-differential mechanisms.
Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
Subjects will have a screening visit for history, medication usage, and blood work; those who qualify will be offered participation. Subjects will be instructed to consume their usual diet, including at least 200 g carbohydrate, and not to engage in strenuous physical activity for the 3 days prior to a study. After an overnight fast they will present to the CRU at the Stedman Building on the Center for Living campus and have intravenous catheters placed in both forearms, one for infusion of test substances and the other for blood sampling; the sampling arm will be warmed with a heating pad to improve venous blood flow. All studies will start following withdrawal of several basal samples over an extended period:

1. Glucagon infusion in fasting and hyperglycemic subjects: dose finding. Subjects receive graded doses of intravenous glucagon after a 12-14 hour fast. Doses will start at 10 ng/kg/min and be increased to 50 and 100 ng/kg/min at 30 minute intervals. Glucose concentrations will be measured at the bedside using a YSI glucose analyzer. Plasma samples will be collected at 10 minute intervals for assay of insulin, C-peptide, and glucagon. These pilot studies will provide insight into the relative sensitivity of hepatic glucose production (fasting study) and insulin secretion (glucose infusion study) to glucagon. These studies will include up to 10 volunteers each.
2. Effects of glycemia to mediate glucagon-stimulated hepatic glucose production (HGP) and insulin secretion. Following placement of intravenous catheters subjects will have an infusion of saline with a tracer dose of deuterated glucose for the remainder of the 300 minute protocol. \[6, 6\]2H2 glucose will be started as a 4 mg/kg bolus over 5 minutes followed by a continuous infusion of 0.020-0.4 mg/kg/min. After a 2 hour equilibration period to label the glucose pool, subjects will have A) saline infusion, B) initiation of a hyperglycemic clamp, C) infusion of exendin-(9-39) 750 pmol/kg/min and a hyperglycemic clamp. The clamp will be generated with the infusion of a 20% solution of dextrose enriched to 2% with deuterated glucose. The infusion rate will be started at 30 mg/kg/h and adjusted every 5 minutes until the blood glucose reaches \~150 mg/dl; the infusion will be adjusted thereafter to maintain this level of glycemia. Blood samples will be taken at 10 minute intervals throughout the study to measure: enrichment with \[6, 6\]2H2 glucose, insulin, glucagon and C-peptide. After 120 minutes of A) tracer alone, B) hyperglycemia, or C) exendin-9 plus hyperglycemia, subjects will receive glucagon as an infusion of 10-100 ng/kg/min for 30 or 60 minutes.

The primary outcome variables from these experiment will be HGP and insulin secretion. The hypothesis to be tested is that glucagon given at fasting glucose levels will cause a rapid rise in HGP and blood glucose (50-150 mg/dl over basal) with a secondary rise of insulin secretion that follows the change in glycemia; and that glucagon given at mild hyperglycemia will promptly stimulate insulin secretion and limit the response of HGP. The protocol and predictions of results are depicted below.
The use of minfulness based programs for body weight control and stress management is increasing. One of the main reasons for this situation is that individuals care more about the diet and body weidght as a result of the increase in health concerns and stress. In addition, such cognitive support programs in the diet process provide a more comfortable and stress-free continuation of the diet. Based on the above-mentioned information; in this study, it is aimed to determine the effect of mindfulness based diet intervention on weight loss and eating behaviuors.

Individuals who meet the research criteria will randomize according to their file numbers (with the ramdomizer program) and divide into 2 groups: mindfulness group (15) and control group . Food consumption records, anthropometric measurements and eating behaviours scale of all individuals will record at the beginning and end of the study. In order to prevent interaction between individuals, all diet programs will prepare at different times and individually.
FOSCAVIR has been associated with changes in serum electrolytes including hypocalcemia, hypophosphatemia, hyperphosphatemia, hypomagnesemia, and hypokalemia (see ADVERSE REACTIONS section). FOSCAVIR may also be associated with a dose-related decrease in ionized serum calcium which may not be reflected in total serum calcium. This effect is likely to be related to chelation of divalent metal ions such as calcium by foscarnet. Patients should be advised to report symptoms of low ionized calcium such as perioral tingling, numbness in the extremities and paresthesias. Particular caution and careful management of serum electrolytes is advised in patients with altered calcium or other electrolyte levels before treatment and especially in those with neurologic or cardiac abnormalities and those receiving other drugs known to influence minerals and electrolytes (see PATIENT MONITORING and Drug Interactions sections). Physicians should be prepared to treat these abnormalities and their sequelae such as tetany, seizures or cardiac disturbances. The rate of FOSCAVIR infusion may also affect the decrease in ionized calcium. Therefore, an infusion pump must be used for administration to prevent rapid intravenous infusion (see DOSAGE AND ADMINISTRATION section). Slowing the infusion rate may decrease or prevent symptoms.
Children with autism spectrum disorder (ASD) often have impaired communication, problems with social interaction, and repetitive and stereotyped patterns of behavior. While most research has attempted to treat the behavioral deficits commonly associated with ASD, few studies have attempted to improve the core features of this disorder. A recent study found that donepezil HCl helped to improve speech production, attention span, and ability to express emotions in a group of children with autism. This study will provide an opportunity to conduct further testing of the effects of donepezil HCl on the cognitive deficits presumed to underlie the core features of ASD.

This study begins at Week 1 with a baseline assessment. Participants are then randomly assigned to either donepezil HCl or placebo. Participants will start with either a 5mg/day dose of donepezil HCl or placebo followed by a cognitive assessment after 4 weeks on this dose. Participants will then have their dose increased to 10mg/day. Another cognitive assessment will be given after 4 weeks on this dose.
The goal of supplement study is to test the feasibility of a self-managed (SM), electronic/mobile Health (e/mHealth) yoga intervention for reducing stress symptoms (burden) in older caregivers (CG) of people with Alzheimer's Disease and related dementia's (PWD). CG burden can exacerbate a myriad of physical and psychosocial comorbidities in CGs as well as PWD neuropsychiatric symptoms. These effects may be further amplified in older CG with underlying health concerns or those who are not able to access programs for effective management of their own medical or self-care needs. Low-impact physical activities such as gentle Yoga (GY) have shown positive effects on mood and symptoms of pain and fatigue in older community dwellers, and digital e/mHealth platforms have a great deal of potential to overcome financial and medical barriers for the delivery SM stress interventions across demographic boundaries. In this study, we will examine the feasibility of a 12-week e/mHealth gentle yoga+yogic breathing (GYYB) intervention for alleviating symptoms of burden in aging CG of PWD (Aim 1); measure initial changes in stress and QoL indicators in CG and PWD (post- vs. pre-intervention) to inform an adequately-powered, future efficacy trial (Aim 2), and; establish a Dyadic Analysis Training Program for Medical University of South Carolina (MUSC) faculty within the College of Nursing and P20 Symptom Self-Management Center (SSMC) to support future research evaluating the influence of care-recipient interactions on health outcomes (Aim 3). Feasibility will be assessed using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, and will include measures such as recruitment, adherence, treatment satisfaction, attrition, and feedback for intervention refinement. Data related to CG physical function, fatigue, depression, social isolation, loneliness, relationship quality, burden, and stress biomarkers, as well as PWD and CG QoL, will be collected via daily electronic practice logs and interviews at study beginning and end. Older (45 yrs. old and older) male and female CG (N=20) of PWD regularly attending respite care (RCC) programs will be recruited from an existing study population (R01 NR016466) participating in CG-RCC mealtime partnerships for improved PWD nutritional outcomes. The HIPAA-compliant GYYB intervention will employ 'tablets' that allow CG to practice GYYB at home by following along with recorded lessons. CG will initially be trained on the use of the tablet and proper GYYB practices by the study coordinator (in-home), with weekly follow up (videoconference/phone) for the duration of the study. This investigation is ideally aligned with the aims of the parent SSMC (P20 NR016575) that are focused on providing infrastructure and community-based resources for design and ecologically-valid testing of self management (SM) interventions for individuals with chronic conditions.
Disclosed is an active ingredient delivery system for extending an in-vivo half-line of an active ingredient. The active ingredient delivery system comprises carrier peptide and the conjugate of the active ingredient. The conjugate has a serum half-line which is extended compared to the peculiar serum half-line of the active ingredient, the carrier peptide is a peptide bonded to albumin in blood in order to extend the serum half-line of the active ingredient. The carrier peptide is a peptide including sequence number 1, a peptide having a sequence homogeny of 80% or more with the peptide sequence, or a fragment of the same. The peptide having a sequence homogeny of 80% or more and the fragment may have a serum albumin bonding function of the sequence number 1 peptide. Using the techniques disclosed in the present invention, an in-vivo half-line of an active ingredient can be extended, and the administered amount and the number of administrations of the active ingredient can be reduced, so that the effects of the active ingredient can be improved.
Prodn. of aerosols in which drug particles are microencapsulated with at least a monolayer of a hydrophobic substance (I) is effected by (a) generating an aerosol stream comprising drug particles in air saturated with water vapour at a preselected temp., (b) generating a stream of gaseous (I) in air satd. with water vapour at the same temp. as in (a), (c) turbulently mixing the two streams, and (d) cooling the mixed stream. A vessel (2) contg. the encapsulating substance, e.g. a fatty acid or fatty alcohol, is immersed in a water bath (3) at a temp. 3 degrees C above the m.pt. of the substance. A humidified air stream (4) is passed through the vessel and into a ring-gap mixer (5) for mixing with drug aerosol. The mixer is also heated by the water bath via PVC tubing (10). The aerosol-conditioning section (9) is heated by a jacket supplied with water from the PVC tubing and is lined with moistened filter paper (8). The condenser (11) is maintained at 15 degrees C.
BACKGROUND: The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) is a questionnaire for evaluating the frequency, severity, and impact on quality of life of persons with. Urinary incontinence is a stigma, and a Nepali version of the change women to persons will help to screen for incontinence, and be valuable for clinicians, researchers, and for persons with urinary incontinence.
METHODS: After receiving ethical clearance and permission from ICIQ, the translation and cross-cultural adaptation was conducted using the ICIQ module protocol. This incorporated initial translation of the questionnaire, backward translation with involvement of ICIQ. The necessary adjustments were made during a meeting with the reconciliation expert team. After the approval from the ICIQ, interviews were conducted with eight women with urinary incontinence for conceptual equivalence. After cognitive debriefing, the comments were checked and proofreading of the questionnaires for comprehensibility, readability and accuracy of the grammar were done. Final typesetting and formatting were checked to match the original ICIQ-UI SF.
RESULTS: The IICIQ-UI SF was successfully translated and cross-culturally adapted while maintaining the characteristics of the original source.
CONCLUSIONS: Through translation, review from the experts and interviews conducted with Nepalese women experiencing urinary incontinence, a relevant and comprehensive ICIQ-UI SF was developed to use in Nepal. The questionnaire will be of great value for clinical use and future studies involving Nepalese women.